Antimicrobial Susceptibility Testing

Dr. Parag Chauhan

Introduction

  • Antimicrobial Susceptibility Testing (AST) determines whether Mycobacterium is susceptible or resistant to anti-tubercular drugs.
  • It plays a vital role in the diagnosis and management of tuberculosis (TB).
  • AST helps clinicians select the most effective treatment for patients.
  • It is essential for the early detection of drug-resistant tuberculosis, including MDR-TB and XDR-TB.
  • Both phenotypic (culture-based) and molecular methods are used for susceptibility testing.
  • Accurate AST reduces treatment failure, disease transmission, and the development of further drug resistance.
  • It is routinely performed in clinical microbiology and tuberculosis reference laboratories.

Principle

The principle of Antimicrobial Susceptibility Testing (AST) is to determine whether Mycobacterium is susceptible (sensitive) or resistant to anti-tubercular drugs by observing its growth in the presence of specific antimicrobial agents.

  • AST evaluates the ability of anti-tubercular drugs to inhibit the growth of Mycobacterium.
  • If the bacterium does not grow in the presence of the drug, it is susceptible (sensitive).
  • If the bacterium continues to grow, it is resistant to the drug.
  • Results help clinicians select the most effective treatment regimen.
  • AST can be performed using phenotypic (culture-based) or molecular methods.
  • Accurate testing is essential for the diagnosis and management of drug-resistant tuberculosis (TB).

Importance of AST

Antimicrobial Susceptibility Testing (AST) is essential for the effective diagnosis and treatment of tuberculosis (TB). It helps determine whether Mycobacterium is susceptible or resistant to anti-tubercular drugs.

  • Identifies drug-resistant Mycobacterium strains.
  • Helps select the most effective anti-tubercular drugs.
  • Prevents treatment failure and relapse.
  • Reduces the spread of drug-resistant TB.
  • Supports appropriate patient management.
  • Improves treatment outcomes and public health.

Specimen Collection

Proper specimen collection is essential for the accurate diagnosis of tuberculosis (TB) and reliable Antimicrobial Susceptibility Testing (AST).

Common Specimens

  • Sputum (most common specimen for pulmonary TB)
  • Bronchoalveolar lavage (BAL)
  • Gastric aspirate (children)
  • Pleural fluid
  • Cerebrospinal fluid (CSF)
  • Lymph node aspirate or biopsy
  • Tissue biopsy
  • Urine (genitourinary TB)

Collection Guidelines

  • Collect specimens in a sterile, leak-proof container.
  • Early morning sputum is preferred for better yield.
  • Collect 3–5 mL of good-quality sputum (not saliva).
  • Label the specimen correctly with patient details.
  • Transport the specimen to the laboratory as soon as possible.
  • Follow biosafety precautions while handling infectious specimens.

Drug Resistance in Mycobacterium

  • Drug resistance in Mycobacterium is the ability of the bacteria to survive and multiply despite treatment with anti-tubercular drugs.
  • It usually develops due to genetic mutations or inappropriate use of antibiotics.

Causes

  • Incomplete or irregular treatment.
  • Incorrect drug combinations or dosage.
  • Poor patient compliance.
  • Transmission of drug-resistant strains.
  • Spontaneous genetic mutations.

Clinical Significance

  • Makes tuberculosis more difficult to treat.
  • Requires longer treatment with second-line drugs.
  • Increases treatment cost and adverse effects.
  • Contributes to the spread of MDR-TB and XDR-TB.
  • Early detection by AST improves patient outcomes.

Types of Drug Resistance

Drug-resistant tuberculosis (DR-TB) is classified based on the resistance of Mycobacterium tuberculosis to one or more anti-tubercular drugs.

1. Mono-Resistant Tuberculosis (Mono-resistant TB)

  • Resistant to one first-line anti-TB drug only.
  • Example: Resistance only to isoniazid (INH).

2. Poly-Resistant Tuberculosis (Poly-resistant TB)

  • Resistant to more than one first-line anti-TB drug, but not simultaneously to both isoniazid and rifampicin.

3. Rifampicin-Resistant Tuberculosis (RR-TB)

  • Resistant to rifampicin (RIF), with or without resistance to other drugs.
  • Detected rapidly by GeneXpert MTB/RIF.

4. Multidrug-Resistant Tuberculosis (MDR-TB)

  • Resistant to at least both isoniazid (INH) and rifampicin (RIF), the two most effective first-line drugs.

5. Pre-Extensively Drug-Resistant Tuberculosis (Pre-XDR TB)

  • MDR/RR-TB with additional resistance to any fluoroquinolone (e.g., levofloxacin or moxifloxacin).

6. Extensively Drug-Resistant Tuberculosis (XDR-TB)

  • MDR/RR-TB with resistance to any fluoroquinolone and at least one Group A drug (e.g., bedaquiline or linezolid).

Methods of AST

Antimicrobial Susceptibility Testing (AST) for Mycobacterium tuberculosis is broadly classified into phenotypic and molecular methods.

1. Phenotypic Methods

  • Phenotypic methods are culture-based techniques used to determine the susceptibility of Mycobacterium tuberculosis by observing its growth in the presence of anti-tubercular drugs.
  • If the bacteria grow despite the presence of a drug, they are considered resistant; if growth is inhibited, they are susceptible.

Principle

Phenotypic methods compare the growth of Mycobacterium on drug-containing media with growth on drug-free control media to determine susceptibility or resistance.

Common Phenotypic Methods

1. Proportion Method

  • Most commonly used conventional method.
  • Compares bacterial growth on drug-containing and drug-free media.
  • Determines whether the isolate is susceptible or resistant.

2. Absolute Concentration Method

  • Determines the minimum concentration of a drug that inhibits bacterial growth.
  • Used mainly in research and reference laboratories.

3. Resistance Ratio Method

  • Compares the drug susceptibility of the test strain with a standard susceptible reference strain.
  • Helps assess the degree of drug resistance.

4. MGIT 960 Drug Susceptibility Testing

  • Automated liquid culture system.
  • Detects bacterial growth rapidly using fluorescence.
  • Widely used for first-line and second-line drug susceptibility testing.

Advantages

  • Considered the gold standard for AST.
  • Detects actual bacterial growth.
  • Can test both first-line and second-line anti-TB drugs.

Limitations

  • Time-consuming because Mycobacterium grows slowly.
  • Requires specialized laboratory facilities and biosafety measures.
  • Delays treatment decisions compared to molecular methods.

Clinical Significance

  • Confirms drug susceptibility and resistance.
  • Essential for diagnosing drug-resistant tuberculosis (DR-TB).
  • Helps clinicians select the most effective anti-tubercular treatment regimen.

2. Molecular Methods

  • Molecular methods are rapid diagnostic techniques used to detect genetic mutations associated with drug resistance in Mycobacterium tuberculosis.
  • Unlike phenotypic methods, they do not require bacterial growth, allowing earlier detection of drug-resistant tuberculosis.

Principle

Molecular methods identify specific gene mutations responsible for resistance to anti-tubercular drugs using DNA-based techniques.

Common Molecular Methods

1. GeneXpert MTB/RIF

  • Rapid molecular test for the detection of Mycobacterium tuberculosis.
  • Simultaneously detects rifampicin resistance.
  • Results are available in about 2 hours.

2. Line Probe Assay (LPA)

  • Detects mutations associated with resistance to isoniazid (INH) and rifampicin (RIF).
  • Can also detect resistance to selected second-line drugs.
  • Provides results within 1–2 days.

3. Whole Genome Sequencing (WGS)

  • Analyzes the complete genome of Mycobacterium tuberculosis.
  • Identifies mutations responsible for resistance to multiple anti-TB drugs.
  • Mainly used in reference laboratories and research.

Advantages

  • Rapid diagnosis of drug-resistant TB.
  • High sensitivity and specificity.
  • Early initiation of appropriate treatment.
  • Reduces the spread of drug-resistant tuberculosis.

Limitations

  • Detects only known resistance-associated mutations.
  • Requires specialized equipment and trained personnel.
  • More expensive than conventional methods.
  • Cannot completely replace culture-based drug susceptibility testing.

Clinical Significance

  • Enables early detection of MDR-TB, RR-TB, and other drug-resistant forms of tuberculosis.
  • Helps clinicians start effective treatment without waiting for culture results.
  • Plays an important role in TB control programs and surveillance.

Comparison of AST Methods

Feature Phenotypic Methods Molecular Methods
Principle Detect bacterial growth in the presence of drugs Detect resistance gene mutations
Time Required Several weeks Hours to a few days
Speed Slow Rapid
Gold Standard Yes No
Common Examples Proportion Method, MGIT 960 GeneXpert, LPA, WGS

Interpretation of Results

AST results determine whether Mycobacterium tuberculosis is susceptible or resistant to anti-tubercular drugs.

  • Susceptible (Sensitive): The bacterium does not grow in the presence of the drug, indicating the drug is effective.
  • Resistant: The bacterium continues to grow despite the presence of the drug, indicating the drug is ineffective.
  • Multidrug Resistance (MDR-TB): Resistance to at least isoniazid (INH) and rifampicin (RIF).
  • Results help clinicians choose the most appropriate treatment regimen.

Advantages

  • Detects drug-resistant Mycobacterium.
  • Helps select the most effective anti-TB drugs.
  • Improves treatment success.
  • Prevents treatment failure and relapse.
  • Reduces the spread of drug-resistant tuberculosis.
  • Supports better patient management.

Limitations

  • Phenotypic methods require several weeks for results.
  • Molecular methods detect only known resistance mutations.
  • Requires specialized laboratory facilities and trained personnel.
  • Molecular tests are relatively expensive.
  • Culture-based testing is still needed to confirm some resistance patterns.

Clinical Significance

  • Essential for the diagnosis of drug-resistant tuberculosis (DR-TB).
  • Enables early and appropriate treatment.
  • Helps prevent the spread of MDR-TB and XDR-TB.
  • Improves patient outcomes and reduces mortality.
  • Supports national tuberculosis control programs and public health.